News & Events
GSK CEO Emma Walmsley Upbeat on RSV Vaccine Arexvy, Unfazed by Zantac Litigation Costs
- December 1, 2023
- Posted by: Admin
- Category: Health Interviews National Health Daily
GSK CEO Emma Walmsley expressed optimism about the success of the respiratory syncytial virus (RSV) vaccine, Arexvy, anticipating sales surpassing a billion pounds in its debut year. Despite ongoing costly litigation over the discontinued drug Zantac, Walmsley affirmed that the legal expenses wouldn’t disrupt the company’s capital plans.
The vaccine, Arexvy, granted approval by the U.S. FDA for adults aged 60 and older, has already seen a robust launch in the United States and is approved in various countries, with plans underway for additional approvals targeting the 50-59 age group.
Walmsley emphasized the significance of Arexvy for GSK’s future growth amidst patent expiries and declining revenue from existing bestsellers. The successful launch of Arexvy alleviated concerns among investors regarding GSK’s drug pipeline strength, particularly after the spin-off of its consumer healthcare business, Haleon, last year, which renewed the company’s focus on vaccines and infectious diseases.
While GSK seized a significant portion of the U.S. RSV vaccine market share, rival Pfizer expressed disappointment in its performance compared to GSK’s vaccine, Abrysvo, aiming to regain market share in the coming year.
Despite the ongoing Zantac litigation, Walmsley assured that any settlement expenses, estimated at $5 billion, wouldn’t hinder capital allocation. GSK shares, trading at nine times expected earnings over the next 12 months, face comparative valuation differences with competitors like AstraZeneca.
Walmsley defended GSK’s drug pipeline, citing increased R&D spending and recent successes, including the approval of Ojjaara for myelofibrosis treatment and a deal with Johnson for hepatitis B therapy. She also highlighted promising late-stage trial data for GSK’s cancer drug Jemperli and the potential of camlipixant for chronic cough treatment as significant opportunities for the company.
For inquiries, story sharing, advertising, or publicity needs on National Health Magazine, contact via email: globalmastersinstitute@gmail.com or WhatsApp only on +234-902 681 2248.